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Results The expression of ZP4 was present in early antral 
follicles and was stronger in mature follicles. The subgroup 
of patients with eumenorrhea and without hyperandrogen-
ism presented the highest expression of ZP4 in ovarian tis-
sue. In one case, we found a mutation of the ZP4 gene. No 
correlations were found between the ZP4 expression level 
and biochemical or clinical indices.
Conclusions Data from this and animal studies suggest a 
possible relationship between androgens and ZP4 expres-
sion. ZP4 expression is highest among patients with PCOS 
and a regular cycle, and this is a consequence of the pres-
ence of mature follicles in this group. In some patients with 
PCOS and infertility, ZP4 mutation can be found.
Keywords Polycystic ovary syndrome · Zona pellucida · 
ZP4 · Oocyte-specific genes
Introduction
Polycystic ovary syndrome (PCOS) is one of the most 
common endocrinopathies, affecting 5–10 % of women of 
reproductive age [1]. The syndrome is a complex phenom-
enon, which involves the reproductive and other systems. 
Most predominant and concomitantly diagnostic features of 
the syndrome include ovulation disorders (oligo- or anovu-
lation), polyfollicular structure of the ovary and hyperan-
drogenemia along with its clinical features, i.e., hirsutism, 
acne and androgenic alopecia. The clinical manifesta-
tions of ovulation disturbances are menstrual disturbances 
(oligomenorrhea and amenorrhea), which are related to 
decreased fertility. In addition, metabolic disturbances 
are common in this syndrome. The incidence of obesity, 
insulin resistance, glucose intolerance and dyslipidemia is 
increased among patients with PCOS [1]. Many factors are 
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common endocrine disorder of unknown pathology, involv-
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believed to play a role in the pathogenesis of PCOS. These 
include environmental, lifestyle and genetic factors [2, 3].
To date, more than 70 genes have been studied in order 
to elucidate whether they play a role in the pathogenesis of 
PCOS. The genes involved in diverse processes that have 
been studied range from those engaged in steroidic hor-
mones synthesis, oocyte development, as well as the genes 
of hormone receptors, through to those important for glu-
cose metabolism, insulin synthesis or action, and energetic 
homeostasis [2, 3]. Recent studies have shown that one 
important pathophysiologic feature of PCOS is an impair-
ment of follicular development and the development of 
oocytes. So far, it is known that the transforming growth 
factor-beta family signaling pathway is disturbed in the 
oocytes of women with PCOS. Some members of this pro-
tein family are expressed exclusively in oocyte, and that is 
why they are referred to as oocyte-specific genes. Distur-
bances concerning the function of oocyte-specific genes are 
thought to play an important role in the pathology of some 
diseases of the reproductive system. They may be impli-
cated in infertility, premature ovarian failure and PCOS [4].
The zona pellucida (ZP) genes are a group of oocyte-
specific genes. ZP is an extracellular matrix that sur-
rounds growing oocytes, ovulated eggs and preimplanta-
tion embryos. These genes play an important role during 
sperm–egg interaction but also in folliculogenesis. ZP4 
glycoprotein was the last ZP protein identified in humans, 
and its exact role is still not fully recognized [5]. All the 
zona proteins possess the archetypal “ZP domain.” This 
“ZP domain” consists of approximately 260 amino acids, 
including eight conserved Cys residues, and is predicted 
to have high β-strand content with additional conservation 
of hydrophobicity, polarity and turn forming tendency at a 
number of positions [14]. The human Zp4 gene (pseudo-
gene in the mouse) of 8226 bp, located on chromosome 1 
(1q43), encodes a 540 amino acids long polypeptide. The 
ZP4 gene covers 12 exons and 11 introns. The open-read-
ing frame contains 1623 bp [6]. On the basis of the ZP4 
expression pattern in the ovary of the rat, it is suggested 
that this gene plays an important role in primordial folli-
cle formation [unpublished data]. Structurally, human ZP4 
protein is most similar to human ZP1 and that is why it was 
previously misidentified as ZP1. It can be supposed that 
ZP4 also can play a role to ensure the integrity of human 
ZP. What is more, studies in humans have proved that ZP4 
take a part in acrosomal reaction [7–9]. ZP4 induces acro-
somal exocytosis through a Gi-independent pathway [8]. 
Binding sites for recombinant ZP4 glycoprotein are located 
both at the N- and C-terminus of proacrosin [10].
Regarding these findings and previous studies of other 
oocyte-specific genes, the aim of this study was to analyze 
the ZP4 coding sequence and its expression in patients with 
polycystic ovary syndrome. We also decided to investigate 
the localization of ZP4 protein in the ovaries of patients 
with PCOS.
Materials
In the study, 87 patients (mean age 24.7 ± 3.91 years; mean 
BMI 24.7 ± 5.2 kg/m2) with PCOS were included. The 
PCOS was diagnosed according to the European Society of 
Human Reproduction and Embryology and American Soci-
ety of Reproductive Medicine (ESHRE/ASRM) criteria 
from 2003, namely: oligo- and/or anovulation (OM), clini-
cal and/or biochemical signs of hyperandrogenism (HA), 
or polycystic ovaries in ultrasound (US), after exclusion of 
other known etiologies. For establishing the diagnosis, two 
out of three criteria must be fulfilled; therefore, four differ-
ent phenotypes of PCOS arise according to the combina-
tion of its three main manifestations: 1: OM + HA + US, 
2: HA + US, 3: OM + US and 4: OM + HA (Table 4).
A total testosterone serum level above 0.8 ng/ml was 
considered as hyperandrogenemia. Patients with a history 
of the following conditions and procedures were excluded: 
ovarian surgery, radio- or chemotherapy, premature ovarian 
failure, hyperprolactinemia, thyroid dysfunction or ovula-
tion induction in the last 3 months.
All the studied subjects gave their written consent to par-
ticipate in the study. The Ethical Commission of Poznan Uni-
versity of Medical Sciences approved the study’s protocol.
Methods
In each case, we took detailed medical history, with spe-
cial emphasis on: the regularity of menses and the age of 
menarche. To assess the phenotype and signs of hyperan-
drogenism, physical and gynecological examination has 
been performed; the hirsutism was quantified on the basis 
of modified Ferriman–Gallwey scale by the same physician 
in each case. To confirm the PCOS diagnosis and exclude 
other possible causes of presented clinical picture, we per-
formed hormonal analysis, which has been made in eumen-
orrheic and oligomenorrheic women in late follicular phase 
(from 10th to 12th day of menstrual period) or in any day 
in amenorrheic patients. Following hormones, concentra-
tions have been measured in serum: estradiol (E2), follicle-
stimulating hormone (FSH), luteinizing hormone (LH), tes-
tosterone (T), dehydroepiandrosterone sulfate (DHEAS), 
17-OH progesterone (17-OHP).
Serum levels of insulin were determined by ELISA 
(Enzymun Test Insulin; Boehringer Mannheim, Mannheim, 
Germany). T, LH, FSH and PRL were measured with 
specific chemiluminescence assays (Chiron Diagnostics 
GmbH, Fernwald, Germany).
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The following were measured with specific RIAs: sex 
hormone-binding globulin (SHBG) (Orion Diagnostica, 
Espoo, Finland), DHEAS (DPC, Los Angeles, CA), and 
17a-hydroxyprogesterone and IGF-I (Biosource Europe 
S.A., Nivelles, Belgium). Sampled sera were stored at 
220 °C until analysis was performed. The free T index 
and the ratio of fasting glucose to insulin were calculated. 
Plasma glucose was determined instantaneously with a 
chemiluminescence assay (Chiron Diagnostics GmbH). 
The intraassay and interassay coefficients of variation were 
10 % for all assays performed.
The blood samples were taken in the morning after at 
least 8 h of fasting and stored at −20 °C for DNA isolation.
Ovarian specimens
Ovarian samples were obtained from 87 women under-
going ovarian wedge resection because of PCOS. All the 
women were recruited from among patients of the Depart-
ment of Gynecological Endocrinology of Poznan Univer-
sity of Medical Sciences. The ethnicity of all subjects was 
Caucasian, and they were unrelated to one another.
The ovary samples were cut into uniform-size slices and 
frozen in −70 °C for further studies.
DNA isolation and PCR amplification
In the women with PCOS, we performed ZP4 gene sequenc-
ing. The DNA was extracted from blood cells using the 
QIAamp DNA Blood Mini Kit (Qiagen). Genomic DNA 
was used for in vitro amplification by PCR with a specific set 
of primers complementary to the coding sequence of the ZP4 
gene (Table 1).
PCR was performed in the UNO II thermocycler (Biom-
etra, Germany). Initial DNA denaturation was performed 
at 95 °C for 5 min, then step 2—denaturation at 95 °C for 
20 s—followed, ensued by primers annealing at 56 °C for 
15 s and elongation at 72 °C for 80 s. The cycle of dena-
turation, annealing and elongation was repeated 35 times 
and followed by final elongation at 72 °C for 5 min. The 
purified PCR products were ligated into a pGEM-T Easy 
vector (Promega). Competent Escherichia coli DH5alpha 
cells were transformed with ligation products. Plasmids 
with inserts were extracted from the white-transformed 
colonies with a QIAprep Plasmid Kit (Qiagen). Inserts 
and PCR products were sequenced with an automated 
3130 × Genetic Analyzer (Applied Biosystems) in the Fac-
ulty of Biology, Adam Mickiewicz University in Poznan. 
The sequences that were obtained were analyzed and com-
pared to those available in the GenBank database (NCBI, 
USA) using BLAST search.
Real-time PCR
The ovarian tissue samples were quickly cut into 30-mg 
samples, placed in 1.5-ml tubes and stored in the RNA sta-
bilization reagent (Qiagen) at −80 °C until further process-
ing. Disruption and homogenization of the tissue samples 
were carried out with a mortar and pestle.
Total RNA was isolated using the RNeasy Mini Kit 
(Qiagen) according to the manufacturer’s instructions. 
After isolation, the RNA was stored at −80 °C.
Reverse transcription and real-time PCR were performed 
with a designed set of primers (Table 2) for the human 
ZP4 (zona pellucida 4) coding sequence, glyceraldehyde-
3-phosphate dehydrogenase (GAPDH), human R2A poly-
merase (polR2a) and human hypoxanthine phosphoribosyl-
transferase 1 (HPRT). The primers were designed to cross 
exon–intron boundaries. The possibility of DNA co-ampli-
fication was excluded from failure of the product detection 
in real-time PCR with the DNA template.
Reverse transcription reactions were conducted using 
the QuantiTect Reverse Transcription Kit (Qiagen) accord-
ing to the manufacturer’s instructions.
Table 1  Primers used for PCR study of ZP4 gene sequence
Primer 
name














Table 2  Primers used for real-time PCR analyses
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The expression level of each gene was measured by 
means of real-time PCR experiments using the QuantiFast 
SYBR Green PCR Kit (Qiagen). Quantification of mRNA 
samples was carried out by relating the PCR threshold 
cycle obtained from tissue samples to specific standard 
curves. The relative abundance of the target was divided by 
the relative abundance of GAPDH, PolR2a and HPRT in 
each sample to generate a normalized abundance (NF–nor-
malization factor).
Immunohistochemistry
Material for immunohistochemical analysis included cut 
fragments of ovarian tissue received from patients with 
polycystic ovary syndrome. Fragments of the ovarian tis-
sue were investigated using immunohistochemical meth-
ods, which included staining using monoclonal antibodies 
from mice (MA-1671 clone) against the human ZP4 anti-
gen, hematoxylin–eosin staining, immunohistochemical 
staining for the presence of alpha-inhibin and PAS reaction 
for the presence of polysaccharides in the tissue. Immu-
noreaction was conducted with the EnVision™+ System 
HRP.
Statistical analysis
Results are presented as means and standard deviation 
[SD]. Statistical analysis was performed using the soft-
ware StatSoft 2011 STATISTICA version 10. The normal-
ity of data distribution was verified with the Shapiro–Wilk 
test. The variables were verified by tests: the parametric 
Student’s t test or nonparametric Mann–Whitney U test. 
A p value ≤0.05 was considered significant. Interactions 
between the variables were tested using Pearson’s linear 
correlation analysis.
Results
ZP4 sequence analysis in blood samples
From a total of 87 patient blood samples with PCOS, 
we identified four nucleotide changes in the ZP4 coding 
sequence: three silent nucleotide changes in exons 1, 4, 
10 and one nucleotide change in the exon 5 (position 114, 
T > G) (Table 3). The mutation in exon 5 (T > G) resulted 
in substitution of cysteine for glycine of the amino acid in 
position 223 of the ZP4 protein. Cysteine in this position 
is strictly conserved in ZP4 protein. The point mutation in 
one of the ZP4 alleles could contribute to the expression of 
two ZP4 protein forms—one protein with normal function 
and one incorrectly folded, with disturbed function of the 
zona pellucida domain.
Ovarian samples: characteristics of women diagnosed 
with PCOS
Because of ethical considerations, we could not collect a 
control group for expression studies. All the surgical proce-
dures performed on gonads bring a risk of reducing the fol-
licular reserve, which is ethically unacceptable in healthy 
women. Instead, we decided to compare the ZP4 expres-
sion level between women with different phenotypes of 
PCOS. The phenotypes were divided according to the Rot-
terdam criteria [1].
Of the 87 PCOS subjects studied, the largest phe-
notype group included women with all three features, 
namely OM + HA + US (38 %, Table 4). Another 16 % 
had HA + US (the ovulatory phenotype), and 14 % had 
OM + US (the nonhyperandrogenic phenotype).
Interestingly, 24 % did not meet the criteria for PCO-
US; these subjects were separately analyzed in the separate 
group OM + HA. The clinical and biochemical characteris-
tics of all the studied groups are shown in Table 4.
Real-time PCR results
The results of the study show that the expression level of 
ZP4 gene in the ovaries of women with PCOS was very 
low comparing to other genes with a constitutive expres-
sion. The mean number of copies for the GAPDH consti-
tutive gene was 39,287, for the PolR2a constitutive gene 
41,854 and for HPRT 22,035.
In the OM + HA + US group, the mean Zp4 expression 
level was estimated as 373.212 ± 341.75 number of cop-
ies, whereas in the HA + US group, it was 852.0 ± 742.0, 
in the OM + US group, it was 636.7 ± 516.51 and in the 
OM + HA group, it was 124.1 ± 137.8. Considering all the 
Table 3  Nucleotide changes in 
the ZP4 coding sequence from a 
total of 87 patient samples with 
PCOS and resulting amino acid 
changes in the ZP4 protein
All changes are monoallelic
Sample no. Exon number  
of ZP4 gene
Nucleotide change,  
(position in exon)
Amino acid change in ZP4 protein, 
(position in protein, gi 10863987)
2 5 T → G, position 114 C → G, position 223
9 4 T → A, position 68 No change
12 10 C → T, position 75 No change
13 1 C → T, position 18 No change
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groups with polycystic ovaries (I + II + III) together, the 
mean expression level in the RT-PCR was 620.6 ± 3780.5 
numbers of copies (Fig. 1). The statistical analysis 
revealed that the differences between all the groups were 
significant p < 0.0001 (ANOVA test). Post hoc analyses 
revealed that the difference was significant between groups 
OM + HA + US and HA + US; HA + US and OM + HA; 
and OM + US and OM + HA.
Correlation analysis
We analyzed the possible correlations between all the 
measured hormones as well as other laboratory data 
(including fasting glucose levels and SHBG), but we found 
no significant correlations between any of those factors and 
the ZP4 expression level. Moreover, we checked also pos-
sible links between the clinical data: age, BMI, Ferriman–
Gallwey score and ZP4 expression, but we did not find any 
significant connections here either.
Immunohistochemical analysis ZP4 protein localization
As we expected, ZP4 protein was localized only in the ovar-
ian follicles. There was no immunohistochemical reaction 
in the primary ovarian follicles (Fig. 2), very low reaction in 
single epithelial cells of secondary ovarian follicles, but very 
intense reaction was observed in follicles with antrum folli-
culi. The reaction intensity was highest in the close proximity 
layer of the follicle, which is corresponding to developing a 
zona pellucida envelope (Fig. 3). It is also suggested from the 
positive PAS reaction that the ZP4 antigen is polysaccharide.
Discussion
The zona pellucida, an acellular glycoprotein matrix sur-
rounding mammalian eggs and early embryos, mediates 
Table 4  Clinical and biochemical characteristics of studied groups
The statistically significant differences between studied and control group are marked: (* OM + HA + US vs OM + US and OM + HA)
Characteristics (mean ± SD) First phenotype: 
OM + HA + US
Second phenotype: HA + US Third phenotype: OM + US Fourth phenotype: 
OM + HA
Age (years) 25.2 ± 5.1 24.1 ± 6.3 25.2 ± 4.8 24.9 ± 5.2
BMI (kg/m2) 24.6 ± 6.2 25.7 ± 6.0 24.6 ± 4.6 24.9 ± 4.9
FSH (mIU/ml) 5.94 ± 1.40 6.61 ± 1.62 6.08 ± 1.89 6.20 ± 1.83
LH (mIU/ml) 10.89 ± 3.52* 14.09 ± 5.26 14.13 ± 6.73* 14.12 ± 6.38*
E2 (pg/ml) 68.35 ± 42.77 62.19 ± 30.15 58.75 ± 29.13 59.52 ± 29.16
T (ng/ml) 0.70 ± 0.29 0.89 ± 0.39 0.78 ± 0.30 0.81 ± 0.33
SHBG (mIU/ml) 51.37 ± 24.52 48.00 ± 24.52 44.93 ± 46.62 45.65 ± 42.32
DHEAS (ng/ml) 3.52 ± 2.73 2.65 ± 1.63 2.89 ± 1.41 2.83 ± 1.45
Insulin (mIU/ml) 10.05 ± 6.92 12.25 ± 10.16 9.19 ± 5.81 9.87 ± 7.04
PRL (ng/ml) 20.47 ± 8.87 18.00 ± 7.50 20.59 ± 14.64 19.97 ± 13.30
Fig. 1  Mean ZP4 expression level in studied groups (vertical—num-
ber of copies)
Fig. 2  Primary ovarian follicles—no immunohistochemical reaction
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sperm–egg interaction, provides a postfertilization block 
to polyspermy and protects the embryo prior to implanta-
tion. The zona pellucida 4 gene (ZP4) is a recently iden-
tified gene from the oocyte-specific gene family. ZP4 has 
been purified by the immunoaffinity column and was iden-
tified as a 65 kDa protein glycolyzed mainly by N-linked 
carbohydrate moieties [11]. The main function of the ZP4 
seems to be the induction of the acrosome reaction and the 
inhibition of the binding of spermatozoa to zona pellucida, 
a function which is shared also by the ZP3 glycoprotein. 
N-Glycolyzation of the protein, along with extracellular 
calcium concentration, is required for the action of ZP4. 
The function is also facilitated by signaling through the 
protein kinase C (PRKCA), kinase A (PRKAR1A), protein 
tyrosine kinase (JAK1), and the L-type and T-type calcium 
channels. G proteins also participated in ZP3-induced, but 
not ZP4-induced, acrosomal reaction [11].
In the presented study, the expression of Zp4 in poly-
cystic ovaries is not compared to healthy controls. Because 
of ethical considerations, we could not collect a sufficient 
number of controls for this study. Obtaining function-
ing ovarian tissue with follicles from healthy women or 
those undergoing surgery for benign lesions has not been 
accepted by ethical committee, since those procedures are 
related to decrease in ovarian reserve. Instead, we com-
pared the different phenotypes of PCOS. There is a lack of 
human data indicating the stage of follicle development and 
ZP4 expression level. The experiments performed on ani-
mal models indicate the scant expression of ZP proteins in 
the early stages of development, which is in line with our 
finding [3–5].
The immunohistochemical analysis revealed the pres-
ence of ZP4 in antral follicles and failed to find a significant 
reaction in the primordial follicles. The strongest reaction 
was present in a layer adjacent to the antral follicle which 
corresponds to the uniform coat that is formed around the 
growing oocyte [3–5].
In our study, we analyzed the ZP4 expression on mRNA 
level in ovarian samples taken during the wedge resection 
of the ovaries of patients diagnosed with different pheno-
types of PCOS. All studied patients have poor response 
to the pharmacological treatment undergoing surgery as 
second-line therapy. In this syndrome, ovarian follicles are 
present in large numbers, but they are arrested at an early 
to mid (early antral follicles)-developmental state and fail 
to mature. Real-time PCR revealed the highest mRNA 
expression of ZP4 in the group of women with eumenor-
rhea (HA + US), and it was comparable to the expression 
in the OM + US group (no statistical difference was pre-
sent between these groups). ZP4 expression was consid-
erably lower in the OM + HA + US phenotype and the 
OM + HA. Keeping in mind the fact that immunohisto-
chemical staining showed the highest expression of ZP4 
in the mature antral follicles, and the highest number of its 
copies in the ovaries of women with eumenorrhea is under-
standable. Only in this group of women were follicles able 
to undergo maturation and express zona pellucida genes, 
whereas in patients with oligomenorrhea, the follicles are 
arrested in the early stages of their development [2]. In 
these stages, the immunohistochemistry showed a very low 
expression. Interestingly, also patients without hyperandro-
genemia had a similar intensity of expression level. From 
animal studies, it is known that androgens regulate the zona 
pellucida genes expression, so it is possible that the lack 
of the excess of testosterone positively influenced the ZP4 
transcription [12, 13]. The lowest levels of expression were 
present in the groups with oligomenorrhea and hyperandro-
genemia, which partially is in line with the above hypothe-
sis. On the other hand, in the correlation analysis, we failed 
to find any direct dependence between the ZP4 expres-
sion level and testosterone, the free testosterone index, 
the DHEAS or the Ferriman–Gallwey score. Considering 
the cited animal data and our data from real-time PCR in 
PCOS, analysis of the relation between androgens and zona 
pellucida genes in humans may have a big scientific poten-
tial [12, 13].
Another important part of our study was the ZP4 
sequence analysis in the blood samples from PCOS 
patients. It showed that ZP4 nucleotide changes are pre-
sent in some patients with PCOS. In one case, mutation in 
position 114, in exon 5, was revealed (Table 3). This muta-
tion results in the substitution of cysteine for the glycine 
of amino acid in position 223 of the ZP4 protein. Cysteine 
in this position is strictly conserved in the ZP4 protein. 
This mutation is located in “ZP domain” module of ZP4 
(corresponds from 188 to 460 aa). ZP domain has been 
shown to play an important role in the polymerization of 
Fig. 3  Very intense immunohistochemical reaction in follicle with 
antrum folliculi
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extracellular matrix proteins, including ZP matrix [14]. 
Whether such mutation affects structure and function of 
ZP4 remains to be determined. Zona pellucida proteins are 
responsible for sperm–oocyte reaction, and recently, it was 
shown that an abnormal ZP1 gene could be responsible for 
familial infertility [9, 15]. The presence of ZP4 gene muta-
tion in one case of PCOS is not sufficient to judge about 
its role in the pathogenesis of PCOS or infertility. How-
ever, taking into account the data from literature and our 
results, this fact indicates we believe the necessity of fur-
ther research in this field.
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